Instruction for use: Tamoxifen citrateI want this, give me price
Active substance Tamoxifen
ATX code L02BA01 Tamoxifen
Estrogens, gestagens; Their homologues and antagonists
Antineoplastic hormonal agents and hormone antagonists
Nosological classification (ICD-10)
C50 Malignant neoplasm of breast
Cancer of the nipple and areola of the breast, Breast carcinoma, The hormone-dependent form of recurrent breast cancer in women in menopause, Hormone-dependent breast cancer, Disseminated breast carcinoma, Disseminated Breast Cancer, Malignant breast cancer, Malignant neoplasm of breast, Contralateral breast cancer, Locally advanced or metastatic breast cancer,Locally-distributed breast cancer, Locally-recurring breast cancer, Metastatic breast carcinoma, Metastasis of breast tumors, Metastatic breast carcinoma, Inoperable breast carcinoma, Incompatible breast cancer, Breast cancer in women with metastases, Breast cancer in men with metastases, Breast Cancer, Breast cancer in men, Mammary cancer, Breast cancer with distant metastases, Breast cancer in postmenopausal women, Breast cancer hormone-dependent, Breast cancer with local metastases, Breast cancer with metastases, Breast cancer with regional metastases,Breast cancer with metastases, Common hormone-dependent forms of breast cancer, Common Breast Cancer, Recurrent Breast Cancer, Recurrence of breast tumors, Breast cancer, Estrogen-dependent breast cancer, Estrogen-Dependent Breast Cancer, Disseminated breast cancer with overexpression of HER2, Tumors of the mammary glands
C75.1 Malignant neoplasm of pituitary gland
Pituitary Tumor, Aumada del Castillo Syndrome, Somatoliberinoma, Pituitary adenoma, Tumors of the pituitary and suprasellar region
D35.2 Benign neoplasm of pituitary gland
Pituitary adenoma, Prolactinomas, Macro-prolaktinoma, Microprolactinoma, Prolactinoma, Somatoliberinoma, Aumada del Castillo Syndrome, Tumors of the pituitary and suprasellar region
D44.3 Neoplasm of uncertain or unknown pituitary nature
Macro-prolaktinoma, Microprolactinoma, Prolactinoma, Somatoliberinoma, Prolactinomas
Composition and form of release
1 tablet contains tamoxifen citrate 10 or 20 mg; In a blister 10 pcs., In a box of 6 or 10 blisters.
Pharmacological action - antitumor, antiestrogenic.
It inhibits the progression of an estrogen-dependent tumor by blocking estrogen receptors. Metabolites of tamoxifen are also antiestrogens.
Absorption is slow. Cmax - after 3-6 hours The stable level of tamoxifen in the serum is usually achieved after 3-4 weeks of taking the drug. Excreted as conjugates (70%) mainly with feces.
Estrogen-dependent breast cancer, pituitary tumors, anovulatory infertility.
Thrombophlebitis, pregnancy, lactation (stop breastfeeding).
Effects caused by anti-estrogenic action: hot flashes, vaginal bleeding, vaginal discharge, itching in the genital area, alopecia, pain in the lesion and in the bones (with metastases).
From the gastrointestinal tract: nausea, vomiting.
From the central nervous system (central nervous system): rarely - dizziness, headache, depression.
Other: increased body temperature, skin rash; Rarely - edema, thromboembolism, phlebitis, visual impairment, thrombocytopenia.
Cytotoxic drugs increase the risk of thrombosis. Potentiates the hypoprothrombotic effect of anticoagulants (eg, warfarin). Affects the level of thyroid hormones in the blood without affecting its function. Tamoxifen should not be given in combination with drugs containing hormones, especially estrogens.
Dosing and Administration
The average daily dose of 20-40 mg (in 1 or 2 doses). The effect of treatment usually appears after 1-3 months of therapy.
With caution appoint the drug to patients with leukopenia, thrombocytopenia, hypercalcemia. In the process of treatment, control of the peripheral blood pattern (including determination of the number of platelets), calcium concentration in the blood, observation of the ophthalmologist is necessary.
People taking tamoxifen should refrain from studies that require increased concentration of attention, rapid mental reactions.
In a dry, the dark place at a temperature of no higher than 30 į C.
Keep out of the reach of children.
Do not use after the expiry date printed on the package.